These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31173910)

  • 21. How many aqueous humor outflow pathways are there?
    Costagliola C; dell'Omo R; Agnifili L; Bartollino S; Fea AM; Uva MG; Zeppa L; Mastropasqua L
    Surv Ophthalmol; 2020; 65(2):144-170. PubMed ID: 31622628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ALK5 inhibitor acts on trabecular meshwork cell and reduces intraocular pressure.
    Aoshima K; Inagaki S; Takagi Y; Nakamura S; Hara H; Shimazawa M
    Exp Eye Res; 2023 Feb; 227():109382. PubMed ID: 36634838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a Novel Intraocular-Pressure-Lowering Therapy Targeting ATX.
    Nagano N; Honjo M; Kawaguchi M; Nishimasu H; Nureki O; Kano K; Aoki J; Komatsu T; Okabe T; Kojima H; Nagano T; Aihara M
    Biol Pharm Bull; 2019; 42(11):1926-1935. PubMed ID: 31685776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research.
    Rao PV; Pattabiraman PP; Kopczynski C
    Exp Eye Res; 2017 May; 158():23-32. PubMed ID: 27593914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intraocular Pressure-Lowering Activity of NCX 470, a Novel Nitric Oxide-Donating Bimatoprost in Preclinical Models.
    Impagnatiello F; Toris CB; Batugo M; Prasanna G; Borghi V; Bastia E; Ongini E; Krauss AH
    Invest Ophthalmol Vis Sci; 2015 Oct; 56(11):6558-64. PubMed ID: 26457541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autonomic drugs in the treatment of canine and feline glaucoma--Part I: Medications that lower intraocular pressure by increasing the outflow of aqueous humour.
    Maślanka T
    Pol J Vet Sci; 2014; 17(4):741-52. PubMed ID: 25638993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trabecular meshwork ECM remodeling in glaucoma: could RAS be a target?
    Agarwal P; Agarwal R
    Expert Opin Ther Targets; 2018 Jul; 22(7):629-638. PubMed ID: 29883239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of 15-keto latanoprost on intraocular pressure and aqueous humor dynamics in monkey eyes.
    Wang RF; Gagliuso DJ; Mittag TW; Podos SM
    Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4143-7. PubMed ID: 17724199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits.
    Isobe T; Mizuno K; Kaneko Y; Ohta M; Koide T; Tanabe S
    Curr Eye Res; 2014 Aug; 39(8):813-22. PubMed ID: 24502505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of glaucoma: focus on pharmacological therapy.
    Marquis RE; Whitson JT
    Drugs Aging; 2005; 22(1):1-21. PubMed ID: 15663346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacology of novel intraocular pressure-lowering targets that enhance conventional outflow facility: Pitfalls, promises and what lies ahead?
    Prasanna G; Li B; Mogi M; Rice DS
    Eur J Pharmacol; 2016 Sep; 787():47-56. PubMed ID: 26948313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of 5-methylurapidil, an alpha 1a-adrenergic antagonist and 5-hydroxytryptamine1a agonist, on aqueous humor dynamics in monkeys and rabbits.
    Wang RF; Lee PY; Mittag TW; Podos SM; Serle JB
    Curr Eye Res; 1997 Aug; 16(8):769-75. PubMed ID: 9255505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of dinucleoside polyphosphates on trabecular meshwork cells and aqueous humor outflow facility.
    Soto D; Pintor J; Peral A; Gual A; Gasull X
    J Pharmacol Exp Ther; 2005 Sep; 314(3):1042-51. PubMed ID: 15947035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of prostaglandins on the aqueous humor outflow pathways.
    Weinreb RN; Toris CB; Gabelt BT; Lindsey JD; Kaufman PL
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S53-64. PubMed ID: 12204701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma.
    Christiansen GA; Nau CB; McLaren JW; Johnson DH
    Ophthalmology; 2004 Sep; 111(9):1658-62. PubMed ID: 15350319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action.
    Sharif NA
    Curr Drug Targets; 2010 Aug; 11(8):978-93. PubMed ID: 20426763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trabecular meshwork as a new target for the treatment of glaucoma.
    Ferrer E
    Drug News Perspect; 2006 Apr; 19(3):151-8. PubMed ID: 16804567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Application of Nitric Oxide for Ocular Hypertension Treatment.
    Han B; Song M; Li L; Sun X; Lei Y
    Molecules; 2021 Dec; 26(23):. PubMed ID: 34885889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension.
    Kaufman PL
    Expert Opin Pharmacother; 2017 Mar; 18(4):433-444. PubMed ID: 28234563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The aqueous humor outflow pathways in glaucoma: A unifying concept of disease mechanisms and causative treatment.
    Braunger BM; Fuchshofer R; Tamm ER
    Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):173-81. PubMed ID: 25957840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.